Santhera Pharmaceuticals (Switzerland) Today
| SANN Stock | CHF 9.46 0.19 1.97% |
Performance0 of 100
| Odds Of DistressOver 65
|
Santhera Pharmaceuticals is selling for under 9.46 as of the 25th of April 2024; that is -1.97 percent decrease since the beginning of the trading day. The stock's lowest day price was 9.14. Santhera Pharmaceuticals has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Santhera Pharmaceuticals Holding are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland. The company has 61.81 M outstanding shares. More on Santhera Pharmaceuticals Holding
Moving against Santhera Stock
| 0.45 | CLN | Clariant AG Earnings Call This Week | PairCorr |
| 0.42 | EVE | Evolva Holding SA | PairCorr |
Santhera Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Santhera Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Santhera Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Santhera Pharmaceuticals Holding (SANN) is traded on SIX Swiss Exchange in Switzerland and employs 39 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 50.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Santhera Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Santhera Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Santhera Pharmaceuticals operates under Healthcare sector and is part of Biotechnology industry. The entity has 61.81 M outstanding shares.
Santhera Pharmaceuticals Holding has accumulated about 21.21 M in cash with (37.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.07.
Check Santhera Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationSanthera Pharmaceuticals maintains a total of 61.81 Million outstanding shares. Santhera Pharmaceuticals has 18.77 % of its outstanding shares held by insiders and 3.5 % owned by institutional holders. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Santhera Ownership Details
Santhera Stock Price Odds Analysis
Depending on a normal probability distribution, the odds of Santhera Pharmaceuticals jumping above the current price in 90 days from now is about 76.53%. The Santhera Pharmaceuticals Holding probability density function shows the probability of Santhera Pharmaceuticals stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Santhera Pharmaceuticals has a beta of 0.7417. This usually implies as returns on the market go up, Santhera Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Santhera Pharmaceuticals Holding will be expected to be much smaller as well. Additionally, santhera Pharmaceuticals Holding has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Santhera Pharmaceuticals to move above the current price in 90 days from now is about 76.53 (This Santhera Pharmaceuticals Holding probability density function shows the probability of Santhera Stock to fall within a particular range of prices over 90 days) .
Santhera Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Santhera Pharmaceuticals market risk premium is the additional return an investor will receive from holding Santhera Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Santhera Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Santhera Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Santhera Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.94 | |||
| Standard Deviation | 2.58 | |||
| Variance | 6.66 | |||
| Risk Adjusted Performance | 0.0024 |
Santhera Stock Against Markets
Picking the right benchmark for Santhera Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Santhera Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Santhera Pharmaceuticals is critical whether you are bullish or bearish towards Santhera Pharmaceuticals Holding at a given time. Please also check how Santhera Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Santhera Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Santhera Pharmaceuticals Corporate Management
Elected by the shareholders, the Santhera Pharmaceuticals' board of directors comprises two types of representatives: Santhera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santhera. The board's role is to monitor Santhera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Santhera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santhera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eva Kalias | Head Communications | Profile | |
| FCMA CGMA | Chief Officer | Profile | |
| Shabir MD | Chief Officer | Profile | |
| Thomas Meier | Founder Chairman | Profile | |
| Dario Eklund | Chief Officer | Profile | |
| Neville MD | Head Management | Profile | |
| Gnther Metz | Head VP | Profile |
How to buy Santhera Stock?
Before investing in Santhera Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Santhera Pharmaceuticals. To buy Santhera Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Santhera Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Santhera Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Santhera Pharmaceuticals Holding stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Santhera Pharmaceuticals Holding stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Santhera Pharmaceuticals Holding, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Santhera Pharmaceuticals Holding?
The danger of trading Santhera Pharmaceuticals Holding is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Santhera Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Santhera Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Santhera Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Santhera Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Santhera Stock analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |